Dr. Marc Pignot
General Manager at Evin Hub
Team
With more than 20 years of experience in the pharmaceutical/medical supply and CRO industries, Dr. Marc Pignot is responsible for the overall management of the Evin Hub.
His work focuses on the implementation and development of real-world evidence and safety programs, among other things. Dr. Pignot is also dedicated to these key areas at ZEG Berlin, where he is Chief Strategy Officer for the Real-World Evidence and Data Safety Analytics department.
Prior to his time at ZEG-Berlin, he was a director at Kendle (now Syneos Health and Kantar Health) responsible for the execution of global clinical trial programs in various therapeutic areas. He also spent several years at Amersham Health and GE Healthcare working on diagnostic imaging and medical device studies. Before embarking on a career in clinical research, he worked at Aventis Pharmaceutical’s global research center in the field of functional genomics and proteomics. He received his PhD in Bioorganic Chemistry from the Max Planck Institute of Molecular Physiology and completed postdoctoral training in Nucleic Acid Chemistry at the University of Frankfurt/Scripps Research Institute (La Jolla).
Nils Kossack is head of data analytics at the Evin Hub. He has over 15 years of experience in the statistical evaluation of routine SHI data and analyzing epidemiological and health economic issues.
During his mathematics studies at the University of Leipzig, he specialized in actuarial mathematics and statistics and passed a predicate exam. While there, he completed a Bachelor of Science in Computer Science.
Nils Kossack has also been applying his expertise in real-world data analysis at the WIG2 Institute since June 2014 as Head of the Healthcare Industry Division and Specialist Coordinator for Analytics.
As Head of Operations at the Evin Hub, Dr. Michael Schultze shapes the development and implementation of efficient processes to harmonize innovation, standardization, and sustainably transform RWE research.
With his many years of expertise in secondary data research, he also taps into previously unused data sources for research using modern technologies and methods, pioneering concepts that can both drive RWE research forward and transform into marketable business models. In addition, Dr. Schultze contributes his expertise as Director of real-world evidence & Data Safety Analytics at ZEG Berlin, where he heads the Department of Secondary Data Research and focuses particularly on the integration of real-world data into clinical research.
Dr. Schultze completed his studies in veterinary medicine at the Ludwig Maximilian University of Munich where he earned his doctorate “summa cum laude.
Dr. Ines Weinhold
Head of Science Management & Communication
E-mail: ines.weinhold@evin-hub.com
LinkedIn
With a wealth of interdisciplinary experience as managing director of the WIG2 institute and as a scientist, Dr. Ines Weinhold enriches the work at the Evin Hub in the fields of brand management and communication, as well as in health economics.
In addition to her work at the Evin Hub, Dr. Ines Weinhold has been managing WIG2 since 2022. Prior to that, she was responsible for the health economics team at WIG2 for more than seven years, as well as numerous projects focusing on real-world evidence studies, the analysis of care structures, and health economic evaluations. She obtained her doctorate in economics in 2022 at the Health Economics Center of the Technical University of Dresden.
After studying economics at the Technical University of Dresden, and a one-year study visit to the University of St. Petersburg, Dr. Weinhold began her career as a research assistant for the Chair of Entrepreneurship and Innovation and the Health Economics Center at the Technical University of Dresden. In addition, has been a lecturer in health economics and integrated care at the Technical University of Dresden and Dresden International University for many years.
JProf. Dr. Dennis Häckl
Head of Scientific Advisory Board
E-Mail: dennis.haeckl@evin-hub.com
LinkedIn
Assistant Professor Dr. Dennis Häckl supports the projects at the Evin Hub with his scientific expertise.
Since January 2022, Dr. Häckl has held Assistant Professorship for Health Economics and Management at the University of Leipzig’s School of Economics, where he conducts interdisciplinary health economic assessments of care structures and health innovations in various areas of the healthcare system. Central to his research are financing mechanisms of the healthcare system, serving as the basis for investigating the economic significance of “diseases of civilization” as further research.
He completed his doctorate with distinction on the subject of “New Technologies in Healthcare: Framework conditions and actors” at the HHL Leipzig Graduate School of Management. He then researched and taught at the Technical University of Dresden and currently still holds teaching positions at Dresden International University. As co-founder of the WIG2 Institute, Dr. Häckl worked for the company as Managing Director and Scientific Director from 2014 until the beginning of 2022.
WIG2 from Leipzig and ZEG Berlin have founded Evin Hub
WIG2 is an independent and impartial research institute for health economics and health systems research. With interdisciplinary expertise, analytical competence and many years of experience in health systems research, the institute has been providing evidence-based answers to complex questions in the healthcare system since it was founded in 2014. Its focus is on providing comprehensive, scientific advice to public clients, third-party sponsors, and companies in the healthcare industry in the form of care analyses, scientific studies and health economic evaluations, among other things. The research services of the WIG2 are based on the goal of continuously advancing the beneficial, cost-effective and interdisciplinary collaboration of all stakeholders in the healthcare sector.
ZEG Berlin is a leader in pharmaco-epidemiological research and specializes in early detection and quantification of safety risks associated with the use of therapeutic, preventive, or diagnostic drugs. In 2021, ZEG Berlin supplemented its traditional research area with a new department for Real-World Evidence (RWE) and Data Safety Analytics. The focus of this new department includes epidemiology, Health Economics and Outcomes Research (HEOR) and drug safety as well as a broad spectrum of therapeutic areas. ZEG Berlin’s many years of experience in the developing and implementing post-authorization studies with primary data is now combined with new access to real-world data and methods, to meet the changing requirements of medical professionals and regulatory authorities.